Use of SABR for selected patients with oligoprogressive (OP) prostate cancer and renal cell carcinoma (RCC) has been shown to have the potential to improve progression-free survival, extend the time to developing new metastatic lesions, and delay time to starting next systemic therapy without adding significant toxicity – although most of these studies have been small Phase II, single institution, or “basket” trials with heterogeneity in histologies and systemic therapies utilized. OP disease is distinct from oligometastatic disease at presentation, with lack of agreement in its definition. Since not all patients appear to benefit from SABR for OP disease, there is a strong need to recognize patient/disease characteristics and use existing biomarkers, such as ctDNA, to best identify patients who will most benefit from local therapy and experience prolonged time to further distant progression requiring change in systemic treatment. While randomized phase III trials evaluating the use of local therapies in the setting of OP prostate and RCC are ongoing, this approach has already been incorporated into the current standard management of these patients. In this activity, we present the current evidence regarding the use of SABR for OP prostate and RCC and recommendations for best current clinical practice in the use of SABR for patients with OP prostate cancer and RCC will be provided using case-based examples.  

This activity is available from July 9, 2026, through 11:59 p.m. Eastern time on July 8, 2028.